Wells Fargo & Company MN Sells 4,641 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Wells Fargo & Company MN cut its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 10.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,491 shares of the biotechnology company’s stock after selling 4,641 shares during the quarter. Wells Fargo & Company MN owned 0.09% of Capricor Therapeutics worth $545,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 700,243 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares in the last quarter. Black Diamond Financial LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth $3,833,000. Charles Schwab Investment Management Inc. increased its position in shares of Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after purchasing an additional 37,868 shares during the period. Finally, Oppenheimer & Co. Inc. raised its stake in Capricor Therapeutics by 52.4% in the fourth quarter. Oppenheimer & Co. Inc. now owns 104,231 shares of the biotechnology company’s stock valued at $1,438,000 after purchasing an additional 35,823 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Trading Down 6.9 %

Shares of NASDAQ CAPR opened at $11.86 on Friday. The company has a market cap of $541.73 million, a price-to-earnings ratio of -11.19 and a beta of 0.85. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40. The stock has a 50-day moving average price of $11.84 and a two-hundred day moving average price of $14.65.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. On average, sell-side analysts predict that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on CAPR. HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.